PhioPharmaceuticalsCorp . (PHIO) Receives Average Recommendation of “Strong Buy” from Brokerages

PhioPharmaceuticalsCorp . (NASDAQ:PHIO) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokers have set a twelve-month consensus target price of $2.00 for the company, according to Zacks. Zacks has also given PhioPharmaceuticalsCorp . an industry rank of 84 out of 255 based on the ratings given to its competitors.

Separately, ValuEngine upgraded PhioPharmaceuticalsCorp . from a “hold” rating to a “buy” rating in a research report on Monday, April 1st.

Shares of NASDAQ PHIO remained flat at $$0.48 during midday trading on Friday. The stock had a trading volume of 469,642 shares, compared to its average volume of 1,546,188. PhioPharmaceuticalsCorp . has a 12 month low of $0.27 and a 12 month high of $3.37. The company has a market cap of $10.77 million, a price-to-earnings ratio of -0.46 and a beta of 2.05.

PhioPharmaceuticalsCorp . (NASDAQ:PHIO) last posted its quarterly earnings results on Wednesday, March 27th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. PhioPharmaceuticalsCorp . had a negative return on equity of 153.67% and a negative net margin of 4,990.20%.

About PhioPharmaceuticalsCorp .

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

See Also: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on PhioPharmaceuticalsCorp . (PHIO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for PhioPharmaceuticalsCorp . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhioPharmaceuticalsCorp . and related companies with's FREE daily email newsletter.